Richard Marsden, CEO of Synairgen plc (LON:SNG), tells Proactive the phase II trial showed that its drug for the sufferers of chronic obstructive pulmonary disease (COPD) has been well tolerated.
“To show the drug was well tolerated was a very important step. In coming days or weeks we will put some further data out, which hopefully will be the biomarker data,” he said.
Price: 160.3 GBX
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...
FOR OUR FULL DISCLAIMER CLICK HERE
Richard Marsden, chief executive of Synairgen plc (LON:SYN), tells Proactive's Andrew Scott data from the ongoing phase II study of their SNG001 drug suggests it's having the desired effect in boosting the antiviral defences of chronic obstructive pulmonary disease (COPD)...
